Abstract 165P
Background
Lung cancer is the most common cancer in men (14.3%) and 3rd most common cancer in female (8.4%) but account for overall highest cancer related mortality (18%). In India, lung cancer is 4th most common cancer both in incidence and cancer related death. NSCLC is the most common type accounting about 80-85% cases and among these adenocarcinoma accounts for more than half and is further defined according to different molecular subtypes by the identification of oncogenic drivers. With recent advances in the knowledge of NSCLC biology, various oncogenic driver mutations are identified which causes aberrant activation of intracellular signaling pathways associated with the sustained growth of lung cancer cells. Research objectives: Evaluation the mutational profile of NSCLC with broad panel-based next-generation sequencing.
Methods
The study was a hospital based prospective, cross sectional descriptive study conducted at a tertiary care center in Northeast India done during the period from 1st january,2022 to 31st December,2022. Ninteen cases of histologically proven meatstatic NSCLC in core biopsy were included in this study.
Results
The age of patients with NSCLC in our study ranged from 48 to 80 years with mean age of 64.36(+/-9.82) years. Majority of the patients in our study were from the age category 71-80 years (37%) Male to female ratio was 19:1 (95% vs 5%). 73.3% of cases were chronic smokers while 26.3% were nonsmokers with smoker non-smoker ratio of 2.79:1.100% of cases presented in late stage (Stages IV). Regarding biomarker profile of NSCLC in our study, EGFR mutation positivity was seen in 10.5%.ALK rearrangement was positive in 5.3% of patients. In our study PD-L1 expression positivity was57.9% and among these patients,18.2% has TPS>50% whereas 81.8% showed TPS<50%.
Conclusions
Adenocarcinoma is the predominant histological subtype of NSCLC in the region of NE India, with a high proportion of cases harboring EGFR mutation. Moreover, NSCLC is characterized with unique mutations and cannot be generalized in larger context. So, study with larger sample size should be encouraged for evaluation of molecular profile of NSCLC in this region.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
Assam Medical College, Dibrugarh.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
93P - A new platform for fast-track molecular stratification of endometrial carcinomas enabling timely treatment decisions in precision oncology
Presenter: Susanne Walz
Session: Cocktail & Poster Display session
Resources:
Abstract
94P - Harnessing circulating tumor DNA in bronchoalveolar lavage fluid for precise molecular diagnosis of NSCLC
Presenter: Frank Borm
Session: Cocktail & Poster Display session
Resources:
Abstract
95P - Automatic data processing to identify EGFR mutations in pathology reports of patients with non-small cell lung cancer (NSCLC)
Presenter: Betzabel Cajiao Garcia
Session: Cocktail & Poster Display session
Resources:
Abstract
96P - Analysis of concordance between microsatellite instability by next generation sequencing (NGS-MSI) and mismatch repair deficiency by immunohistochemistry (IHC-MMR) in endometrial cancer (EC) patients
Presenter: Simona Duranti
Session: Cocktail & Poster Display session
Resources:
Abstract
97P - Prospects of liquid biopsy in determining prognosis in children with HGG and DIPG
Presenter: Olga Regentova
Session: Cocktail & Poster Display session
Resources:
Abstract
98P - Liquid biopsy in NSCLC: A promising tool to predict immunotherapy response
Presenter: Ana Fernández
Session: Cocktail & Poster Display session
Resources:
Abstract
99P - Comprehensive genomic sequencing as an ancillary diagnostic tool for pathologists
Presenter: Dan Miller
Session: Cocktail & Poster Display session
Resources:
Abstract
100P - Standard serum biomarkers to help predict a cancer diagnosis in patients with non-specific symptoms: Data from Guy´s rapid diagnostic clinic
Presenter: Maria Monroy Iglesias
Session: Cocktail & Poster Display session
Resources:
Abstract
101P - Patient-derived organoids to optimize CDK4/6 inhibitor-based treatment selection in early breast cancer
Presenter: Carla Alves
Session: Cocktail & Poster Display session
Resources:
Abstract
102P - MicroRNAs in urine and saliva as non-invasive biomarkers of minimal residual disease in pediatric acute lymphoblastic leukemia
Presenter: Alejandra Pando-Caciano
Session: Cocktail & Poster Display session
Resources:
Abstract